Immunovia carries out a rights issue of units of approximately SEK 70 million and raises bridge loans
Summary
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.LUND, Sweden, May 20, 2024 /PRNewswire/ -- The Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") has today, subject to approval by the Annual General Meeting on 19 June 2024, resolved to carry out an issue of shares and warrants ("units") with preferential rights for the Companys existing shareholders of initially approximately SEK 70 million (the "Rights Issue"). This discovery represents a significant breakthrough and marks an important milestone in the Companys quest for early detection of pancreatic cancer.To ensure the accuracy and efficiency of the new test, Immunovia has partnered with leading scientists and experts in the field. To the extent any guarantors fulfilment of their guarantee commitment entails that the investment must be approved by the Inspectorate of Strategic Products in accordance with the Swedish Screening of Foreign Direct Investments Act (Sw. lagen (2023:560) om granskning av utl\xe4ndska direktinvesteringar), such part of the guarantee is conditional upon notification that the application of the transaction is left without action or that approval has been obtained from the Inspectorate of Strategic Products.Lock-up agreements In connection with the Rights Issue, all shareholding members of the Board of Directors and senior management in Immunovia have undertaken towards Vator Securities AB, subject to customary exceptions, not to sell or carry out other transactions with a similar effect as a sale unless, in each individual case, first having obtained written approval from Vator Securities AB. The information was submitted for publication, through the agency of the contact persons set out above, at 23.45 CET on 20 May 2024.Immunovia in brief Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.Immunovias shares (IMMNOV) are listed on Nasdaq Stockholm.